Mark Sabag - 09 Dec 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Reporting relationship: Executive Vice President, International Markets Commercial
Issuer ticker: TEVA
Reported as of: 09 Dec 2025
Net transaction value: -$4,021,301
SEC form: 4
Accepted by SEC: 11 Dec 2025, 16:06:35 UTC
Prior SEC filing: 12 May 2025
Next SEC filing: 29 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Dov Bergwerk as attorney-in-fact for Mark Sabag

Key filing fact

Mark Sabag filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 11 Dec 2025.

Key facts

This page summarizes Mark Sabag's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 Dec 2025, 16:06.

Change

Previous filing in this sequence was filed on 12 May 2025.
Current net transaction value: -$4,021,301.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001721442 Primary reporting owner

Sabag Mark

Relationship: Executive Vice President, International Markets Commercial
Address: C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL
Signature: /s/ Dov Bergwerk as attorney-in-fact for Mark Sabag
Signature date: 11 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TEVA transaction

Ordinary Shares

Options Exercise

Transaction value: $2,209,454
Shares: +118,724
Change %: +79%
Price: $18.61
Shares after: 269,720
Date: 09 Dec 2025
Ownership: Direct
Footnotes: F1

TEVA transaction

Ordinary Shares

Sale

Transaction value: $3,413,078
Shares: -118,724
Change %: -44%
Price: $28.75
Shares after: 150,996
Date: 09 Dec 2025
Ownership: Direct
Footnotes: F1, F2

TEVA transaction

Ordinary Shares

Sale

Transaction value: $2,817,677
Shares: -98,168
Change %: -65%
Price: $28.70
Shares after: 52,828
Date: 09 Dec 2025
Ownership: Direct
Footnotes: F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TEVA transaction Derivative

Stock Options (right to buy)

Options Exercise

Transaction value: $0
Shares: -118,724
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 09 Dec 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 118,724
Exercise price: $18.61
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.705 to $28.845, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.675 to $28.745, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F4

Stock options were granted on February 9, 2018, with 39,574 vested on each of February 9, 2020, February 9, 2021 and February 9, 2022.

SEC remarks

Executive Vice President, International Markets Commercial